- Home
- RNXT vs MDAI Comparison
RNXT vs MDAI Comparison
Compare RNXT & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- MDAI
- Stock Information
- Founded
- RNXT 2012
- MDAI 2013
- Country
- RNXT United States
- MDAI United States
- Employees
- RNXT N/A
- MDAI N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- RNXT Health Care
- MDAI Health Care
- Exchange
- RNXT Nasdaq
- MDAI Nasdaq
- Market Cap
- RNXT 44.6M
- MDAI 51.5M
- IPO Year
- RNXT 2021
- MDAI N/A
- Fundamental
- Price
- RNXT $1.30
- MDAI $2.53
- Analyst Decision
- RNXT Strong Buy
- MDAI Strong Buy
- Analyst Count
- RNXT 2
- MDAI 2
- Target Price
- RNXT $7.25
- MDAI $4.75
- AVG Volume (30 Days)
- RNXT 145.6K
- MDAI 608.4K
- Earning Date
- RNXT 08-12-2025
- MDAI 08-11-2025
- Dividend Yield
- RNXT N/A
- MDAI N/A
- EPS Growth
- RNXT N/A
- MDAI N/A
- EPS
- RNXT N/A
- MDAI N/A
- Revenue
- RNXT $240,000.00
- MDAI $29,962,000.00
- Revenue This Year
- RNXT $3,186.05
- MDAI N/A
- Revenue Next Year
- RNXT $291.93
- MDAI $15.14
- P/E Ratio
- RNXT N/A
- MDAI N/A
- Revenue Growth
- RNXT N/A
- MDAI 55.21
- 52 Week Low
- RNXT $0.75
- MDAI $0.82
- 52 Week High
- RNXT $1.69
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- RNXT 49.27
- MDAI 67.28
- Support Level
- RNXT $1.27
- MDAI $2.07
- Resistance Level
- RNXT $1.42
- MDAI $2.22
- Average True Range (ATR)
- RNXT 0.06
- MDAI 0.17
- MACD
- RNXT -0.02
- MDAI 0.03
- Stochastic Oscillator
- RNXT 25.00
- MDAI 73.08
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.